| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| before September | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| before October | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| before November | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| before December | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| before 2027 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| before April 2027 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This market asks when Beam Therapeutics will submit a Biologics License Application (BLA) to the U.S. FDA for Risto-cel, a late‑stage product candidate. The timing matters because a BLA submission is a major regulatory milestone that precedes approval decisions and commercial planning.
A BLA is filed after a company believes it has sufficient clinical, safety, and chemistry/manufacturing/control (CMC) data to request U.S. marketing authorization for a biologic. Timing depends on completion and analysis of pivotal trials, resolution of any safety signals, CMC scale‑up and validation, and prior regulatory interactions such as pre‑BLA meetings or rolling submissions. Corporate strategy, partner arrangements, and resource allocation can also speed up or delay the submission.
Market prices for this event reflect traders’ collective expectations about when Beam will submit the BLA for Risto-cel and update as new public information appears. Use those prices as a real‑time signal of changing expectations, while also tracking independent regulatory and clinical announcements.
Key signals include announcement of positive pivotal trial top‑line or full results, disclosure of a pre‑BLA meeting with FDA or a rolling submission, public statements about completed CMC validation batches or facility readiness, and formal updates about planned submission timing from company press releases or investor presentations.
Designations like Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), or Priority Review can shape regulatory expectations and review paths; however, this primarily affects review timing rather than the company’s decision to file. Pre‑BLA meetings and formal FDA requests for additional data or manufacturing information can materially alter submission timing.
A complete BLA requires detailed CMC documentation demonstrating consistent, scalable manufacturing and product quality. Delays commonly arise from the need to complete process validation, resolve comparability issues, obtain release data for validation lots, or prepare facilities for FDA inspection.
Monitor pivotal trial primary endpoint results, durability or long‑term follow‑up data, safety and adverse event reports, supportive Phase 1/2 evidence if referenced in the submission, and any subgroup analyses or biomarker data the company highlights in communications.
Beam’s senior management and regulatory team decide when the BLA package is sufficiently complete to file; external partners may also influence timing. The primary regulator for a U.S. BLA is the FDA, with potential parallel or subsequent filings to other national authorities depending on company strategy.